This is a numbers-first look at Torrent Pharmaceuticals Ltd. (TORNTPHARM), covering income trends, margins, valuation, and shareholding.
Torrent Pharma Revenue Trend
The top line tells a positive story: Torrent Pharmaceuticals Ltd.'s revenue advanced 21.4% to ₹13,980 Cr in FY2026.
The 10-year revenue CAGR of 7.7% reflects steady — if not spectacular — top-line expansion from ₹6,676 Cr to ₹13,980 Cr.
In terms of scale, Torrent Pharmaceuticals Ltd.'s ₹13,980 Cr in annual revenue positions it as a major pharmaceuticals company.
Looking at the year-on-year numbers, Torrent Pharmaceuticals Ltd. has seen 9 years of unbroken revenue growth.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹13,980 Cr | +21.4% |
| FY2025 | ₹11,516 Cr | +7.3% |
| FY2024 | ₹10,728 Cr | +11.5% |
| FY2023 | ₹9,620 Cr | +13.1% |
| FY2022 | ₹8,508 Cr | — |
View Torrent Pharmaceuticals Ltd.'s full 10-year revenue trend with CAGR analysis →
Torrent Pharma Profitability
A 11.9% improvement in net profit took Torrent Pharmaceuticals Ltd.'s bottom line to ₹2,138 Cr in FY2026.
Net margin thinned to 15.3% in FY2026, compared to 16.6% the year before.
On an EPS basis, the company earned ₹63.92 (diluted) in FY2026 versus ₹56.47 in FY2025.
Is Torrent Pharma Undervalued
Torrent Pharmaceuticals Ltd. shares are currently trading at ₹5,050.00.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Torrent Pharma Shareholding Pattern
Promoters continue to hold 68.3% of the company, unchanged over recent quarters.
On the foreign institutional side, the holding is 15.4% as of June 2026 — down from 15.9%.
The DII stake stands at 9.8% as of June 2026, versus 9.3% in the year-ago period.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 68.3% | 15.4% | 9.8% | 6.4% |
| Mar 2026 | 68.3% | 16.2% | 9.1% | 6.5% |
| Dec 2025 | 68.3% | 16.1% | 9.1% | 6.4% |
| Sep 2025 | 68.3% | 15.9% | 9.3% | 6.5% |
Track quarterly shareholding changes for Torrent Pharmaceuticals Ltd. →
Torrent Pharma Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2026 total assets: ₹443.13B (up 195.6% YoY from ₹149.90B).
Top categories: Intangibles & Goodwill (63.8%), Property, Plant & Equipment (10.6%), Inventories (7.1%).
Of the ₹443.12B in liabilities and equity, 39.7% is shareholder equity, 33.9% is interest-bearing debt, and 26.4% is operating liabilities. Over the year, debt is up 369.2% and equity is up 131.7%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 19.83B |
| Receivables | 30.31B |
| Inventories | 31.38B |
| Property, Plant & Equipment | 47.04B |
| Investments | 826.20M |
| Intangibles & Goodwill | 282.70B |
| Other Assets | 31.05B |
| Category | Value |
|---|---|
| Equity | 175.85B |
| Short-term Debt | 31.84B |
| Long-term Debt | 118.41B |
| Trade Payables | 23.58B |
| Other Liabilities | 93.44B |
Torrent Pharma — The Bottom Line
To sum up Torrent Pharmaceuticals Ltd.'s financial position: the data paints a clear picture for investors evaluating this pharmaceuticals stock.
Revenue of ₹13,980 Cr in FY2026, up 21.4% year-over-year.
Long-term revenue has been compounding at 7.7% annually over 10 years.
The company is profitable, with a net margin of 15.3% and net income of ₹2,138 Cr.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Torrent Pharmaceuticals Ltd..